Skip to main content
Journal cover image

438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress)

Publication ,  Conference
André, T; Bekaii-Saab, T; Tabernero, J; Siena, S; Yoshino, T; Norwood, KG; Adelberg, DE; Ward, J; Yang, S; Strickler, JH; Van Cutsem, E
Published in: Annals of Oncology
September 2022

Duke Scholars

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2022

Volume

33

Start / End Page

S734 / S735

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
André, T., Bekaii-Saab, T., Tabernero, J., Siena, S., Yoshino, T., Norwood, K. G., … Van Cutsem, E. (2022). 438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress). In Annals of Oncology (Vol. 33, pp. S734–S735). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.576
André, T., T. Bekaii-Saab, J. Tabernero, S. Siena, T. Yoshino, K. G. Norwood, D. E. Adelberg, et al. “438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress).” In Annals of Oncology, 33:S734–35. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.576.
André T, Bekaii-Saab T, Tabernero J, Siena S, Yoshino T, Norwood KG, et al. 438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress). In: Annals of Oncology. Elsevier BV; 2022. p. S734–5.
André, T., et al. “438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress).” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S734–35. Crossref, doi:10.1016/j.annonc.2022.07.576.
André T, Bekaii-Saab T, Tabernero J, Siena S, Yoshino T, Norwood KG, Adelberg DE, Ward J, Yang S, Strickler JH, Van Cutsem E. 438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress). Annals of Oncology. Elsevier BV; 2022. p. S734–S735.
Journal cover image

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2022

Volume

33

Start / End Page

S734 / S735

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis